Celebrating #Diwali is a beloved tradition at Stoke. As the Festival of Lights, our team looks forward to celebrating together every year with lights, food, and a sense of community. This meaningful holiday symbolizes renewal, unity, and togetherness – all values that resonate deeply within our team. #StokedAboutStoke
Stoke Therapeutics
Biotechnology Research
Bedford, Massachusetts 12,811 followers
About us
Stoke Therapeutics (Nasdaq: STOK), is a biotechnology company dedicated to addressing the underlying cause of severe diseases. The company is pursuing an entirely new approach to treating severe diseases. We are initially focused on diseases of the central nervous system and the eye, with an emphasis on haploinsufficiencies, which are diseases caused by a loss of about half of the normal protein function. Rather than replace, repair or edit faulty genes, we aim to increase – or stoke – protein output from healthy genes to restore functional protein levels using our proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) platform. In all, Stoke has identified ~6500 genes with a TANGO signature, representing broad potential for our approach to help people with severe diseases. The early results have been promising. Stoke’s first medicine in development, STK-001 has demonstrated positive Phase 1/2 results for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy that is associated with a number of debilitating non-seizure comorbidities. Behind that, is STK-002, a potential treatment for autosomal dominant optic atrophy (ADOA), the most common inherited optic nerve disorder. Clinical studies of STK-002 are anticipated to start in 2024. The company is pursuing potential treatments for three additional neurodevelopmental disorders, including Syngap1 and Rett syndrome, in collaboration with Acadia Pharmaceuticals. Stoke is headquartered in Bedford, Massachusetts with offices in Cambridge, Massachusetts.
- Website
-
https://www.stoketherapeutics.com/
External link for Stoke Therapeutics
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- Bedford, Massachusetts
- Type
- Public Company
- Founded
- 2017
Locations
-
Primary
Get directions
45 Wiggins Ave
Bedford, Massachusetts 01730, US
Employees at Stoke Therapeutics
Updates
-
We’re proud to support Biomedical Science Careers Program (BSCP)’s Evening of Hope, an event dedicated to advancing opportunities for underrepresented minorities and inspiring future leaders in biomedical sciences. The work of BSCP in fostering diversity and inclusion is critical in shaping the future of healthcare. We’re honored to support their important mission. Together, we can continue to break down barriers and create pathways for the next generation of experts in science and medicine. #BSCP #eveningofhope2024
To say that our paddle raise portion of the event was a rousing success would be an understatement!! Thank you so much to the BSCP community!! #fundthemission #bscp #eveningofhope
-
Today on #SUDEPActionDay2024, we’re raising awareness about Sudden Unexpected Death in Epilepsy (SUDEP) and the importance of understanding this serious risk. Raising awareness about the risks associated with epilepsy is essential. Taking an active role in discussing, reviewing, and reducing these risks helps ensure that those affected by epilepsy can live safer and healthier lives. We stand with the epilepsy community and support families navigating these challenges. Learn more and get involved: https://lnkd.in/em8nkZy #SUDEP #OurRisksOurRights
Today is #SUDEPActionDay2024 & we are uniting with organisations around the world to raise awareness of the rights of people with epilepsy or those bereaved by it. The epilepsy community is entitled to have their questions answered and have the right to information, medication and care. Share our posts and tag us @sudepaction
-
-
Stoke Therapeutics reposted this
I'm elated to share that our manuscript titled “Antisense Oligonucleotide STK-002 Increases OPA1 in Retina and Improves Mitochondrial Function in Autosomal Dominant Optic Atrophy Cells” was recently accepted for publication in Nucleic Acid Therapeutics and is now available online! https://lnkd.in/etXWiw4t This study presents preclinical data that support the progression of STK-002 towards the clinic as the first potential disease-modifying treatment for autosomal dominant optic atrophy (ADOA), an inherited disease that often leads to blindness and currently has no treatment. A heartfelt thank you to my amazing colleagues and mentors at Stoke Therapeutics who contributed their time, expertise, and passion to this project. Your dedication and collaboration were invaluable and made this accomplishment possible. Reflecting on this journey, I’m reminded of how fulfilling and satisfying it is to engage in research that not only pushes the boundaries of knowledge but also holds the potential to make a difference in the lives of patients suffering from severe genetic diseases. It’s a powerful reminder of why we do what we do at Stoke! #oligonucleotide #antisense #RNA #ADOA #OPA1 #biotech
-
Today, Stoke announced highlights from presentations at the 15th European Epilepsy Congress related to the Company’s work to develop the first disease-modifying medicine for #Dravetsyndrome. Learn more in our press release: https://lnkd.in/dxKt8Pbm #ILAE #EEC2024 International League Against Epilepsy
-
-
Stoke is pleased to announce the appointment of Eric Olson as Chief Business Officer. Mr. Olson brings two decades of successful corporate business development experience with an emphasis on #rarediseases and #RNA therapeutics https://lnkd.in/eT4Nk7bv
-
Today we announced upcoming investor conference presentations at H.C. Wainwright & Co., LLC’s 26th Annual Global Investment Conference and Cantor Fitzgerald’s 2024 Global Healthcare Conference. Learn more: https://lnkd.in/d8bErxUj #CantorHCC #Biotech #innovation #investment
-
The Stoke team is heading to the International League Against Epilepsy's 15th European #Epilepsy Congress in Rome! We look forward to sharing encore data from our #Dravetsyndrome clinical program. Learn more about our upcoming presentations: https://lnkd.in/eWNxNQGC #EEC2024 #ILAE
-
#ICYMI Our co-founder Isabel Aznarez discussed how her early research in human genetics inspired her and put her on the path to dedicate her life to science. Learn more about Isabel’s background, what led her to start Stoke, and the work her team is doing to target the underlying cause of severe diseases with a unique RNA-based approach. #StokedAboutStoke #RNA #biotech #innovation BiotechTV, Brad Loncar
𝐓𝐡𝐞 𝐁𝐚𝐜𝐤𝐬𝐭𝐨𝐫𝐲: During a visit to Stoke Therapeutics yesterday, we met co-founder Isabel Aznarez and heard the story of how the company was founded and why the focus on gene expression upregulation. See more at BiotechTV.com. BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Theragent Inc | NYSE | Allucent
-
Our CEO Edward M. Kaye, MD sat down with Brad Loncar of BiotechTV to discuss why he’s so excited to be leading Stoke in our mission to change the way severe diseases are treated by upregulating protein expression with #RNA-based medicines. #StokedAboutStoke #biotech #leadership
𝐁𝐞𝐡𝐢𝐧𝐝 𝐭𝐡𝐞 𝐒𝐜𝐢𝐞𝐧𝐜𝐞: Stoke Therapeutics' CEO Edward M. Kaye, MD on using RNA medicines to upregulate protein expression, and the company's progress in Dravet Syndrome. He describes the unique science that Stoke was founded on, how phase 1/2a data in Dravet appears to show they are reversing this genetic condition, and how he views the company's protein upregulation approach as a broader platform. Full video: https://lnkd.in/gP-CWf9p BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Theragent Inc | NYSE | Allucent